How GLP-1 direct-to-consumer programs are distorting utilization trends
Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to...
Regulatory decision-making depends on evidence that reflects how medical products perform in real-world use, not only in controlled trials. For more than a decade, the Food and Drug Administration has relied on real-world data and real-world...
Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Artificial intelligence is no longer something healthcare and life sciences teams are testing on...
Regulatory decision-making depends on evidence that reflects how medical products perform in...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Early signals indicate continued declines in influenza vaccination uptake and shifts in the...
Our team had a great time at HCIC connecting with healthcare marketers, digital teams and consumer...
Real-world evidence (RWE) studies often stall on the same friction points: defining the most...
Veterans Day invites us to look beyond branch and rank to the people and stories behind the...
Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to grow across obesity and metabolic disease, but the way patients access these therapies is changing in ways that complicate traditional research approac...